OTC:PLSH
PANACEA LIFE SCIENCES HOLDINGS, INC.
A life sciences entity with modest 2023 revenue of $2.4M but facing substantial liquidity constraints and negative operating cash flows.
Key Metrics
Investment Thesis
Bull Case
PLSH may represent a turnaround opportunity if successful new drug candidates or medical technologies are brought to market, potentially unlocking significant value from its intangible assets and goodwill of $3.0M. The recent reduction in accounts receivable changes suggests improved collection efficiency, which could help stabilize working capital once revenue scales.
Bear Case
The stock carries extreme risk due to a negative shareholders' equity of -$8.3M and a current ratio well below 1.0, indicating an imminent solvency threat without external financing. Investors should avoid the ticker as the company is burning through cash reserves with no clear path to profitability amidst heavy interest obligations.
About PANACEA LIFE SCIENCES HOLDINGS, INC.
Panacea Life Sciences Holdings (PLSH) operates within the healthcare and life sciences sector, focusing on pharmaceutical development and potentially related medical services. The company serves markets requiring specialized therapeutic solutions, though specific product lines are inferred from its operating structure. With total assets of $18.0M and a significant retained earnings deficit of -$33.9M, the firm navigates capital-intensive research phases.
Analysis
Management Discussion
Despite a modest revenue increase from $1.6M in 2022 to $2.4M in 2023, the company continues to lose money, posting a net loss of -$8.0M driven by high general and administrative costs of $1.5M and significant non-operating losses of -$2.5M. Cash flow from operations turned negative at -$1.5M while capital expenditures consumed $65k, resulting in a cash burn that has deepened the accumulated deficit to -$33.9M.
Industry Overview
The life sciences industry is characterized by high R&D costs, long development cycles, and regulatory hurdles that can delay revenue recognition for years. Companies in this sector often operate at a loss during early stages but require substantial capital injections to survive until market approval or commercialization milestones are reached.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 |
|---|---|---|
| Revenue | $1.6M | $2.4M |
| Cost of Revenue | $1.2M | $1.3M |
| Gross Profit | $396.5K | $1.1M |
| Operating Expenses | $6.0M | $6.7M |
| Operating Income | $-5.7M | $-5.5M |
| G&A | $1.1M | $1.5M |
| Depreciation | $1.7M | $1.7M |
| Amortization | $61.4K | — |
| Other OpEx | $5.0M | $5.2M |
| Non-Operating Income | $-3.5M | $-2.5M |
| Interest Expense | $2.0M | $1.6M |
| Pre-Tax Income | $-9.1M | $-8.0M |
| Income Tax | $0 | $0 |
| Continuing Ops | $-9.1M | $-8.0M |
| Discontinued Ops | $0 | $0 |
| Net Income | $-9.1M | $-8.0M |
| Minority Interest | $0 | $0 |
| Net to Common | $-9.1M | $-8.0M |
| Metric | 2022 | 2023 |
|---|---|---|
| Current Assets | $6.4M | $4.7M |
| Cash & Equivalents | $7.0K | $100.9K |
| Marketable Securities | $1.1M | $14.9K |
| Accounts Receivable | $206.1K | $264.0K |
| Inventory | $4.4M | $4.0M |
| Prepaid Expenses | $113.1K | $263.0K |
| Other Current Assets | $500.0K | $0 |
| Long-Term Assets | $13.1M | $13.3M |
| PP&E (Net) | $7.7M | $6.4M |
| Intangibles | — | $3.0M |
| Goodwill | $2.2M | $3.0M |
| Operating Leases | $3.2M | $3.9M |
| Other LT Assets | $0 | $-3.0M |
| Total Assets | $19.5M | $18.0M |
| Current Liabilities | $15.1M | $19.4M |
| Current Leases | $2.1M | $2.9M |
| Other Current Liab | $13.0M | $16.5M |
| Long-Term Liabilities | $6.6M | $6.8M |
| LT Operating Leases | $3.0M | $3.3M |
| Other LT Liab | $3.6M | $3.6M |
| Total Liabilities | $21.6M | $26.3M |
| Shareholders' Equity | $-2.1M | $-8.3M |
| Paid-In Capital | $23.8M | $25.6M |
| Retained Earnings | $-25.9M | $-33.9M |
| Total L&E | $19.5M | $18.0M |
| Metric | 2022 | 2023 |
|---|---|---|
| Net Income (CFO) | $-9.1M | $-8.0M |
| Non-Cash Adjustments | $5.2M | $4.6M |
| Working Capital Changes | $1.5M | $1.9M |
| Cash from Operations | $-2.4M | $-1.5M |
| Capital Expenditures | $243.8K | $65.3K |
| Cash from Investing | $-197.0K | $-65.3K |
| Cash from Financing | $2.6M | $1.7M |
| FX Effect | $0 | $0 |
| Net Change in Cash | $-12.8K | $94.0K |
| Beginning Cash | $19.8K | $7.0K |
| Ending Cash | $7.0K | $100.9K |
Frequently Asked Questions
How does PANACEA LIFE SCIENCES HOLDINGS, INC. make money?
Pharmaceutical Research and Development, Medical Technology or Equipment Distribution (inferred from CapEx patterns), and potentially Contract Research Services based on operational leverage.
What are the main risks for PLSH?
Severe liquidity crisis with current liabilities ($19.4M) exceeding current assets ($4.7M), persistent net losses of $8.0M annually, high interest expense burden of $1.6M relative to cash holdings, and a negative operating profit margin indicating unsustainable burn rates.
What is PLSH's competitive advantage?
Specialized expertise in niche therapeutic areas, potential proprietary intellectual property portfolios not yet fully monetized, and a lean operational footprint allowing for rapid pivots in research focus.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.